United States===Food and Drug Administration

The United States===Food and Drug Administration is changing its long-standing requirement of two rigorous studies for new drug approvals to a default of one study, aiming to accelerate drug development and availability. This shift reflects modern scientific advances and a move towards greater flexibility in drug reviews.

The United States===Food and Drug Administration proposed new guidelines to streamline the approval process for customized treatments for rare diseases, potentially opening up new commercialization opportunities for pharmaceutical companies. This move aims to remove barriers and encourage scientific advances in rare disease treatments.

The United States===Food and Drug Administration is experiencing a high-profile executive departure, which has led to speculation about potential shifts in its regulatory approach, particularly concerning gene therapies and rare disease drugs. The agency has faced criticism regarding its review processes under Vinay Prasad's leadership.

The United States===Food and Drug Administration approved leucovorin for cerebral folate deficiency, but explicitly stated it does not extend to autism, clarifying earlier public statements.

The United States===Food and Drug Administration is facing scrutiny due to potential conflicts of interest involving its top drug regulator, Tracy Beth Høeg, and her efforts to expedite a petition for new antidepressant warnings. This situation could undermine the agency's scientific integrity and lead to legal challenges.